Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylmalonic acid--an endogenous toxin?

S Kölker1, J G Okun

  • 1Department of General Pediatrics, Division of Inborn Metabolic Diseases, University Children's Hospital, Im Neuenheimer Feld 150, 69120, Heidelberg, Germany. Stefan.Koelker@med.uni-heidelberg.de

Cellular and Molecular Life Sciences : CMLS
|March 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotypic and phenotypic spectrum of cytosolic phosphoenolpyruvate carboxykinase deficiency.

Molecular genetics and metabolism·2022
Same author

Trimethylamine-N-oxide is elevated in the acute phase after ischaemic stroke and decreases within the first days.

European journal of neurology·2020
Same author

Cardiac phenotype in propionic acidemia - Results of an observational monocentric study.

Molecular genetics and metabolism·2020
Same author

The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer.

Oncogene·2017
Same author

MRI and (1)H-MRS in adenosine kinase deficiency.

Neuroradiology·2016
Same author

Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.

Leukemia·2015

Methylmalonic acidurias may involve other metabolites, not just methylmalonic acid, in causing neurological damage. Further research is needed to determine methylmalonic acid's role in kidney complications associated with these conditions.

Area of Science:

  • Biochemistry
  • Metabolic disorders
  • Neuroscience

Background:

  • Methylmalonic acid was historically viewed as the primary neurotoxin in methylmalonic acidurias.
  • Recent research suggests other propionyl-coenzyme A metabolites contribute to neuropathogenesis through synergistic mitochondrial energy metabolism inhibition.

Purpose of the Study:

  • To investigate the role of methylmalonic acid in the development of chronic renal failure in methylmalonic acidurias.
  • To explore potential alternative mechanisms beyond direct toxicity in the organ manifestations of methylmalonic acidurias.

Main Methods:

  • Analysis of metabolite profiles in patients with methylmalonic acidurias.
  • In vitro studies assessing the impact of methylmalonic acid and related metabolites on renal cell function.

Related Experiment Videos

  • Comparative studies examining neurological and renal outcomes in relation to metabolite levels.

    • Main Results:

    • Evidence suggests that metabolites other than methylmalonic acid are key drivers of neurological impairment in methylmalonic acidurias.
    • The specific role of methylmalonic acid in the pathogenesis of chronic kidney disease in these disorders remains to be elucidated.
    • Synergistic effects of propionyl-coenzyme A derivatives on mitochondrial function are critical for understanding disease mechanisms.

    Conclusions:

    • The understanding of methylmalonic acidurias' pathogenesis is shifting from methylmalonic acid as the sole neurotoxin to a broader consideration of co-metabolites.
    • Further investigation is required to clarify the contribution of methylmalonic acid to renal manifestations, particularly chronic renal failure.